Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ELMUMY

Financiado

Cerrado

Elucidation of risk factors and health determinants associated with PROGRESSION...

Elucidation of risk factors and health determinants associated with PROGRESSION of Monoclonal Gammopathies to Multiple Myeloma Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently there is no effective cure since eventually the disease develops resistance to all the available therapeutic approaches. Althoug... ver más

31/12/2026

UOA

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-01

HORIZON-MISS-2021-CANCER-02-03: Better understanding of the impact... ExpectedOutcome:This topic will contribute to the achievement of the mission’s goal through a better...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UOA

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SESAHME Spatially rEsolved Single-cell Approaches in Haematologic Ma... 174K€ Cerrado

OPTATIO OPtimizing TArgets and Therapeutics In high risk and refract... 4M€ Cerrado

bECOMiNG spontaneous Evolution and Clonal heterOgeneity in MoNoclonal... 2M€ Cerrado

TOP TOwards Personalized medicine defining the role of the bone... 275K€ Cerrado

BRIDGES Bioinformatic approaches to identify and detect both disease... 183K€ Cerrado

MYELOMANEXT Integrated next generation flow cytometry and sequencing to... 1M€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2023-01-01
Fecha Fin: 2026-12-31

Líder del proyecto

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently there is no effective cure since eventually the disease develops resistance to all the available therapeutic approaches. Although recent advances have expanded our understanding of the cellular functions associated with health to disease transition, recurrence and response to therapy, critical aspects of this complex pathology remain to be elucidated. Application of omics technologies, and bioinformatics approaches on highly annotated samples obtained from all informative states (monoclonal gammopathy of undetermined significance [MGUS], smoldering MM [sMM], active MM [MM]) could identify biological pathways and molecules responsible for the onset, progression and resistance to therapy of Multiple Myeloma. In parallel, particular emphasis will be given to elucidating the health determinants and risk factors associated with progression to active MM from MGUS/sMM by using extensive demographic, lifestyle and exposure datasets. MGUS is present in 3-5% of the ageing European population and every year, 1% progress to incurable MM that imposes a significant burden on EU societies and health systems. Thus, the best chances of curing MM may be in preventing its progression in the first place. Moreover, there is need of experimental models that recapitulate myeloma progression.We propose an interdisciplinary approach bringing together clinicians and researchers aiming to integrate epidemiological, clinical and experimental datasets in order to create a molecular model of cellular processes associated with the onset of active MM and response to therapy. The proposed systems medicine approach could yield clinically actionable molecular features that could improve MM patient management. Moreover, the integration of lifestyle, clinical and omics information will provide specific profiles for each patient allowingpersonalized diagnosis, prevention, and therapeutic approaches.This action is part of the Cancer Mission cluster of projects on ''Understanding'.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores